• Skip to main content
  • Skip to navigation
Accessibility
  • Increase font size
  • Decrease font size
  • Sharpen color
  • Grayscale
  • Invert color
  • Default
Disclaimerclose
Home

YEDA Technology Transfer from the Weizmann Institute of Science

Yeda Research and Development

Contact Us
Briefcase
Become a member
Menu
  • Home
  • About Us
    • About Us
    • Board of Directors
    • For Entrepreneurs
    • Our Team
    • Close
  • Technologies
    • AgroTech & FoodTech
    • BioPlatforms
    • ClimateTech
    • DeepTech
    • Diagnostics
    • Material Science
    • MedTech & Digital Health
    • Research Tools
    • Software & Algorithms
    • Therapeutics
    • Close
  • Success Stories
  • Our spinoffs
  • News & Events
    • News & Events
    • Newsletters
    • Close
  • For researchers
  • Become a Member
  • Close
  • Technologies(157)
  • Research Experts(103)
  • Success Stories(2)
  • Our Spinoffs(55)
  • News & Events(175)

You are here

  1. Home ›
  2. Search ›
  3. Technologies

Results for technologies (3)

Advanced filter
Therapeutics

MMP14 targeting natural antibodies to treat ovarian cancer (No. T4-2152)

MMP14 is a major antibody target on the tumor cell surface as it is highly expressed on tumor cells and plays a key role in cancer progression and metastasis. Natural occurring autoantibodies targeting MMP14 were isolated from ovarian cancer patients.  Monoclonal antibody therapy... Read more
Full Professor Irit Sagi

Irit Sagi

Faculty of Biology

Share buttons
Share on facebook
Share on twitter
Share on Google +
Share with Email
17825
Therapeutics

Anti-LOX for the Treatment of Duchenne, Fibrosis and Cancer (No. T4-1913)

LOX is a key driver of fibrosis and tumor progression through its role in extracellular matrix remodeling. We developed a set of LOX inhibitors based on LOX’s natural prodomain (LPD) to treat fibrosis, Duchenne Muscular Dystrophy (DMD), and cancer. Treatment of fibrotic disease... Read more
Full Professor Irit Sagi

Irit Sagi

Faculty of Biology

Share buttons
Share on facebook
Share on twitter
Share on Google +
Share with Email
6026
Therapeutics

Targeted Inhibition of ADAM17 for the Treatment of Inflammatory Diseases and Cancer (No. T4-1628)

ADAM17 is a metalloprotease that regulates shedding of membrane-bound proteins, including IL-6, TNF-α, and others. ADAM17 is implicated in inflammatory diseases, fibrosis, cancer, and autoimmune conditions, making it a compelling target. Treatment of autoimmune, inflammatory and ... Read more
Full Professor Irit Sagi

Irit Sagi

Faculty of Biology

Share buttons
Share on facebook
Share on twitter
Share on Google +
Share with Email
5551

User login

  • Request new password
  • Home
  • About Us
    • About Us
    • Board of Directors
    • For Entrepreneurs
    • Our Team
    • Close
  • Technologies
    • AgroTech & FoodTech
    • BioPlatforms
    • ClimateTech
    • DeepTech
    • Diagnostics
    • Material Science
    • MedTech & Digital Health
    • Research Tools
    • Software & Algorithms
    • Therapeutics
    • Close
  • Success Stories
  • Our spinoffs
  • News & Events
    • News & Events
    • Newsletters
    • Close
  • For researchers
  • Become a Member
  • Close

footer

Yeda Research & Development Co. Ltd, P.O Box 95, Rehovot 7610002, Israel
Tel. +972.8.9470617 | Fax. +972.8.9470739
Privacy-Policy youtube twitter facebook linkedin instagram